New results from two large clinical trials are expected to have an immediate impact on the care of patients with the most common form of lung cancer. The drugs tested in the trials, brigatinib (Alunbrig) and durvalumab (Imfinzi), respectively, are already being used to treat some patients with the disease, non-small cell lung cancer (NSCLC). Lung cancer experts agreed that the trials' findings should further cement the value of these drugs in treating NSCLC and continue an important trend.